Ocriplasmin for symptomatic vitreomacular adhesion.
D054598:Blue Cross Blue Shield Insurance Plans; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D022001:Focal Adhesions / Q000187:drug effects*; D006801:Humans; D058449:Intravitreal Injections; D010446:Peptide Fragments / Q000627:therapeutic use*; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
D005343:Fibrinolytic Agents; D010446:Peptide Fragments; D005341:Fibrinolysin